Study Purpose:
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.Study Status:
Not recruiting
Disease:
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Study Type:
Interventional
Type of Intervention:
Drug
Intervention Name:
BIIB067
Placebo:
No
Phase:
Phase 3
Study Chair(s)/Principal Investigator(s):
Medical Director, Biogen
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Study Sponsor:
Biogen
Estimated Enrollment:
138
Estimated Study Start Date:
03 / 08 / 2017
Estimated Study Completion Date:
06 / 13 / 2024
Posting Last Modified Date:
09 / 10 / 2021
Date Study Added to neals.org:
03 / 03 / 2017
Minimum Age:
18 Years
Maximum Age:
N/A
Can participants use Riluzole?
Yes
Key Inclusion Criteria:- Must have diagnosis of superoxide dismutase 1-amyotrophic lateral sclerosis (SOD1-ALS), and must have completed the End of Study Visit for either Parts A, B, or C of Study 233AS101 (NCT02623699) (i.e., were not withdrawn).
- If taking riluzole, participant must be receiving a stable dose for ≥30 days prior to Day 1.
- If taking edaravone, participant must have initiated edaravone ≥60 days (2 treatment cycles) prior to Day 1. Edaravone may not be administered on dosing days during this study.
- Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.
- For female participants of childbearing potential must agree to practice effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment.
- Participants from Study 233AS101 Parts A and B must have a washout ≥16 weeks between the last dose of study treatment received in Study 233AS101 and the first dose of BIIB067 received in the current Study 233AS102.
Key Exclusion Criteria:
- History of allergies to a broad range of anesthetics.
- Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally and could place a participant at an increased risk for bleeding during or after a Lumbar Puncture (LP) procedure. These risks could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von Willebrand's disease, liver disease).
- Presence of an implanted shunt for the drainage of CSF or an implanted central nervous system (CNS) catheter.
- Prior or current treatment with small interfering ribonucleic acid (RNA), stem cell therapy, or gene therapy.
- Treatment with another investigational drug, biological agent (excluding BIIB067), or device within 1 month or 5 half-lives of study agent, whichever is longer.
- Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system (DPS) during the study period.
- Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or pyrimethamine.
- Female participants who are pregnant or currently breastfeeding.
- Current enrollment in any other interventional study.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Research Site
Phoenix, Arizona
85013
United States
Research Site
La Jolla, California
92093-0949
United States
Research Site
San Francisco, California
94118
United States
Research Site
Jacksonville, Florida
32224
United States
Research Site
Miami, Florida
33136
United States
Research Site
Orlando, Florida
32806
United States
Research Site
Atlanta, Georgia
30322
United States
Research Site
Chicago, Illinois
60611
United States
Research Site
Baltimore, Maryland
21287
United States
Research Site
Boston, Massachusetts
02114
United States
Research Site
Rochester, Minnesota
55905
United States
Research Site
Saint Louis, Missouri
63110
United States
Research Site
Lincoln, Nebraska
68510
United States
Research Site
Cleveland, Ohio
44106
United States
Research Site
Portland, Oregon
97213
United States
Research Site
Knoxville, Tennessee
37920
United States
Research Site
Leuven 3000
Belgium
Research Site
Calgary, Alberta
T2N 4Z6
Canada
Research Site
Edmonton, Alberta
T6G 2B7
Canada
Research Site
Toronto, Ontario
M4N 3M5
Canada
Research Site
Montreal, Quebec
H3A2B4
Canada
Research Site
Clermont-Ferrand cedex, Puy De Dome
63003
France
Research Site
Ulm, Baden Wuerttemberg
89081
Germany
Research Site
Torino 10126
Italy
Research Site
Bunkyo-ku
Japan
Research Site
Kagoshima-shi
Japan
Research Site
Shinjuku-ku
Japan
Research Site
Suita-shi
Japan
Research Site
Christchurch 8011
New Zealand
Research Site
Sheffield, South Yorkshire
S102HQ
United Kingdom